Goodbye, Chicago: Takeda sets December deadline for U.S. employees' Boston move

fiercepharma | June 27, 2019

Goodbye, Chicago: Takeda sets December deadline for U.S. employees' Boston move
In the wake of its 64 billion dollars buyout of Shire early last year, Takeda Pharmaceuticals outlined an ambitious consolidation of its operations in the Boston area. For the drugmaker’s 1,000 employees in the Chicago suburbs, that planned move now has a deadline. Takeda will empty its 77,000-square-foot Deerfield, Illinois headquarter facility by Dec. 31 as part of the relocation of its U.S. operations that the Tokyo drugmaker planned after it closed its purchase of Shire in January. Following the move of the 1,000 employees on site, the company is expected to put the Deerfield facility up for sale by March of next year. As part of the move, Takeda will temporarily reassign some of its Deerfield employees to work remotely while others will be assigned to a “transitional work location” in nearby Bannockburn, Illinois, according to Takeda spokesperson Julia Ellwanger. The company said it expects to lay off some of its Deerfield workers, but it didn't disclose job cut numbers. “In cases where there isn’t a solution that meets the business and/or an employee’s needs, the employee will be provided with severance and transition support programs,” Ellwanger said. “Because these discussions are ongoing, we are not providing numbers.”

Spotlight

The monitoring of biotechnological fermentation processes, used for the production of modern biopharmaceutical drugs, is becoming ever more relevant for the promotion of economic production, particularly within the manufacturing sector. Up until now, biotechnical techniques have typically been monitored through off-line analysis, which is laborious, costly and frequently delivers results too late to allow for corrective actions.

Related News

Citius Pharmaceuticals Achieves Chemical Manufacturing and Control Milestones for Mino-Lok

Citius Pharmaceuticals | September 23, 2020

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has achieved a number of significant milestones over the past several weeks for Mino-Lok®. Mino-Lok is an antibiotic lock solution being developed as an adjunctive therapy for patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloodstream infections (CRBSIs). Mino-Lok contains three active drug substances (minocycline, ethanol and EDTA) which are combined into two vials, MLT01 (minocycline) and MLT02 (ethanol and EDTA). Citius has manufactured three registration lots of Mino-Lok using the commercial manufacturing process, which will be filed in the planned New Drug Application (NDA).

Read More

CSA Medical Announces First Procedure in the SPRAY-CB Pivotal Trial for the Treatment of Chronic Bronchitis

CSA Medical Inc | October 22, 2020

CSA Medical Inc., a developer of medical devices advancing the power of liquid nitrogen spray cryotherapy, today announced the first patient treated in the SPRAY-CB, U.S. pivotal trial utilizing the RejuvenAir® System for COPD with Chronic Bronchitis at Temple University. Gerard J. Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University (LKSOM) and Director of the Temple Lung Center, and principal investigator completed the procedure on October 14th. "We are pleased to have performed the first procedure in this landmark pivotal trial, building on the European data in which patients achieved meaningful improvements in their cough and overall quality of life," said Dr. Criner. "RejuvenAir Metered Cryospray is a promising new interventional tool that has the potential to reduce emergency hospital visits due to chronic bronchitis symptoms. This definitive intervention may provide a long-term benefit to millions of adults suffering with Chronic Bronchitis."

Read More

PHARMA TECH

Biomind Labs Announces Design of a Pharmaceutical Form for Psychedelic Drug Delivery Using 3D Printing

Biomind Labs | November 25, 2021

Biomind Labs Inc. a leading biotech company in fast-acting psychedelics is pleased to announce the successful design of an oromucosal solid pharmaceutical form obtained by 3D printing using selective laser sintering. The form contains as its active ingredients certain psychedelic molecules that the Company has in its portfolio of psychedelic candidates. This pharmaceutical form is aimed at alleviating neurological and psychiatric disorders, and acting as an anti-inflammatory agent for various inflammatory disorders. “We believe we are the first company in the world to design a pharmaceutical form for psychedelic drug delivery using 3D printing. This paramount step in our rapid evolution towards becoming a pharmaceutical company, was achieved by our team of scientists who have designed a novel pharmaceutical form to be used with our psychedelic candidates. We are very proud of how our research and development division advances in the development of complex products, on-demand products, and customized products, aimed to address a wide range of needs from patients with different mental health conditions. 3D printing allows creating three-dimensional objects layer by layer, thereby achieving products with variable geometries. Inside the universe of pharmaceutical technology, 3D printing allows combining of shapes and stratification of materials; thus, possibly controlling the time and place of drug release. One of the most interesting and potentially exciting results is that doses can be adjusted in real time for the specific needs of each patient. 3D printing of psychedelics could be key to the future of the industry, not just because it allows us to personalize medicine but also for creating sustainable production, while reducing the environmental burden”, commented Alejandro Antalich, CEO of Biomind Labs. About Biomind Labs Inc. Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of the main psychedelic molecules, DMT, 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biomind Labs’ focus is to provide patients access to affordable and modern-day treatments and use cases.

Read More

Spotlight

The monitoring of biotechnological fermentation processes, used for the production of modern biopharmaceutical drugs, is becoming ever more relevant for the promotion of economic production, particularly within the manufacturing sector. Up until now, biotechnical techniques have typically been monitored through off-line analysis, which is laborious, costly and frequently delivers results too late to allow for corrective actions.